NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Leverkusen, May 23, 2023 — Bayer AG on Tuesday effectively positioned brand-new senior bonds with an overall volume of 3 billion euros under its Debt Issuance Program. The issuance consists of 3 tranches and had to do with 4 times covered. Bayer means to note the bonds on the Regulated Market of the Luxembourg Stock Exchange. The earnings are to be utilized for basic business functions.
The 3 tranches with volumes of 750 million euros, 750 million euros and 1.5 billion euros have maturities of 3.25 years, 6.25 years and 10 years, respectively. The discount coupons of the notes are 4.000 percent p.a., 4.250 percent p.a. and 4.625 percent p.a., respectively. The notes have actually been provided in denominations of 1,000 euros.
The notes are anticipated to be ranked Baa2, BBB and BBB+ by Moody’s, Standard & & Poor’s and Fitch, respectively.
“The high level of oversubscription of our brand-new bonds shows financiers’ self-confidence in Bayer’s advancement,” stated Bayer CFO Wolfgang Nickl.
BofA Securities, Citi and Deutsche Bank led the deal as Joint Active Bookrunners.
About Bayer
Bayer is an international business with core proficiencies in the life science fields of healthcare and nutrition. Its product or services are created to assist individuals and the world prosper by supporting efforts to master the significant difficulties provided by a growing and aging worldwide population. Bayer is devoted to driving sustainable advancement and producing a favorable effect with its companies. At the exact same time, the Group intends to increase its making power and develop worth through development and development. The Bayer brand name represents trust, dependability and quality throughout the world. In financial 2022, the Group utilized around 101,000 individuals and had sales of 50.7 billion euros. R&D costs before unique products totaled up to 6.2 billion euros. To find out more, go to www.bayer.com
Follow us on twitter.com/bayer
Disclaimer
This release does not make up a deal of securities for sale or a solicitation of a deal to acquire securities. Neither this statement nor anything consisted of herein will form the basis of, or be trusted in connection with, any deal or dedication whatsoever in any jurisdiction.
This release is an ad for the functions of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and underlying legislation. The prospectus connecting to the securities explained herein, when released, will be readily available on the site of the Luxembourg Stock Exchange (www.bourse.lu.
A financial investment choice concerning the securities must just be made on the basis of the prospectus.
Positive Statements
This release might consist of positive declarations based upon present presumptions and projections made by Bayer management. Different recognized and unidentified dangers, unpredictabilities and other elements might cause product distinctions in between the real future outcomes, monetary scenario, advancement or efficiency of the business and the quotes offered here. These aspects consist of those gone over in Bayer’s public reports which are offered on the Bayer site at www.bayer.comThe business presumes no liability whatsoever to upgrade these positive declarations or to adhere them to future occasions or advancements.
Extra Information
This statement does not make up a deal to offer or a solicitation of a deal to buy any securities in the United States. Any securities described herein have actually not been and will not be signed up under the U.S. Securities Act of 1933, as changed (the “Securities Act”), or the laws of any state within the U.S., and might not be used or offered in the United States missing registration or a suitable exemption from registration or in a deal exempt to the registration requirements of the Securities Act. There will be no offering of the securities in the United States. This release and the info included herein might not be dispersed or sent out into the United States, or in any other jurisdiction in which provides or sales of the securities explained herein would be restricted by relevant laws and need to not be dispersed to publications with a basic flow in the United States. The securities are being used and offered outside the United States just in dependence on Regulation S under the Securities Act.
In the United Kingdom, this statement is just being dispersed to and is just directed at (i) individuals who have expert experience in matters associating with financial investments falling within Article 19( 5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) and (ii) high net worth entities falling within Article 49( 2) of the Order and (iii) individuals to whom it would otherwise be legal to disperse it (all such individuals together being described as “appropriate individuals”). The securities described herein are just readily available to, and any invite, deal or contract to subscribe, purchase or otherwise obtain such securities will be participated in just with, pertinent individuals. Anybody who is not an appropriate individual must not act or depend on this statement or any of its contents.